Cargando…
Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic
OBJECTIVE: Given the increased use of hydroxychloroquine (HCQ), chloroquine (CQ), and azithromycin (AZM) during the early months of the coronavirus disease 2019 (COVID-19) pandemic, there is a need to evaluate the associated safety concerns. The objective of this study was to summarize the adverse d...
Autores principales: | Dauner, Daniel G., Dauner, Kim Nichols |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Pharmacists Association®. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833798/ https://www.ncbi.nlm.nih.gov/pubmed/33546986 http://dx.doi.org/10.1016/j.japh.2021.01.007 |
Ejemplares similares
-
Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders
Publicado: (2022) -
An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19
por: Shahsavarinia, Kavous, et al.
Publicado: (2021) -
Did States With More Social Capital Pre-pandemic Offer Mental Health Protection During the COVID-19 Pandemic? A Cross-Sectional View
por: Dauner, Kim Nichols, et al.
Publicado: (2022) -
Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022) -
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels
por: Szendrey, Mark, et al.
Publicado: (2021)